Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Besic, Nikola ^a   Satej, Nika ^b  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b Primary Healthcare Research and Development Institute   (Slovenia)

Author keywords

Breast; Diabetes mellitus; Insulin; Oncology

Indexed keywords

ANTIDIABETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GLARGINE; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 84885447768     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-416     Document Type: Article

References (19)

1. Diabetes mellitus and risk of breast cancer: a meta-analysis. Larsson SC, Mantzoros CS, Wolk A, Int J Cancer 2007 121 856 862 10.1002/ijc.22717 17397032 (Pubitemid 47106217)
2. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Bowker SL, Yasui Y, Veugelers P, Johnson JA, Diabetologia 2010 53 1631 1637 10.1007/s00125-010-1750-8 20407744
3. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM, J Clin Oncol 2009 27 3297 3302 10.1200/JCO.2009.19.6410 19487376
4. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Bowker SL, Majumdar SR, Veugelers P, Johnson JA, Diabetes Care 2006 29 254 258 10.2337/diacare.29.02.06.dc05-1558 16443869 (Pubitemid 44106500)
5. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT, Diabetologia 2009 52 1732 1744 10.1007/s00125-009-1418-4 19565214
6. Does diabetes therapy influence the risk of cancer? Smith U, Gale EA, Diabetologia 2009 52 1699 1708 10.1007/s00125-009-1441-5 19597799
7. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G, Diabetologia 2009 52 1745 1754 10.1007/s00125-009-1444-2 19588120
8. Insulin glargine use and short-term incidence of malignancies-a three-year population-based observation. Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdòttir S, Steineck G, Acta Oncol 2011 50 685 893 10.3109/0284186X.2011.558913 21506898
9. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H, Diabetes Metab Res Rev 2009 25 41 49 10.1002/dmrr.912 19145584
10. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type 1 diabetes: a pilot study on MCF-7 breast cancer cells. Mayer D, Chantelau E, Arch Physiol Biochem 2010 116 73 78 10.3109/13813451003631439 20199195
11. Sobin LH, Gospodarowicz MK, Wittekind C, TNM classification of malignant tumours Oxford: Wiley-Blackwell 7 2009
12. ASA physical status classifications: a study of consistency of ratings. Owens WD, Felts JA, Spitznagel EL Jr, Anesthesiology 1978 49 239 243 10.1097/00000542-197810000-00003 697077 (Pubitemid 9032534)
13. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ, N Engl J Med 2003 48 1625 1638 (Pubitemid 36459468)
14. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ, Am J Epidemiol 2004 159 1160 1167 10.1093/aje/kwh161 15191933 (Pubitemid 38747263)
15. Diabetes mellitus and breast cancer: a retrospective follow-up study. Unterburger P, Sinop A, Noder W, Berger MR, Fink M, Edler L, Schmähl D, Ehrhart H, Onkologie 1990 13 17 20 10.1159/000216712 2186318 (Pubitemid 20120773)
16. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R, Kaufman B, Eur J Cancer 2006 42 1077 1082 10.1016/j.ejca.2006.01.027 16574404
17. Diabetes mellitus and breast cancer. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B, Lancet Oncol 2005 6 103 111 10.1016/S1470-2045(05)01736-5 15683819 (Pubitemid 40197704)
18. Breast cancer: biological characteristics in postmenopausal type 2 diabetic women: identification of therapeutic targets. Guastamacchia E, Resta F, Mangia A, Schittulli F, Ciampolillo A, Triggiani V, Licchelli B, Paradiso A, Sabbà C, Tafaro E, Curr Drug Targets Immune Endocr Metabol Disord 2003 3 205 209 10.2174/1568008033340199 12871027
19. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM, Diabetes Care 2010 33 1997 2003 10.2337/dc10-0476 20551014